Viridian Therapeutics, Inc.DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.DE price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Viridian Therapeutics, Inc.DE's price to sales ratio was 49.8× on Nov 11, 2026, against 37.1× a year earlier. Over the last 5 years it ranged from 3.5× to 488.3×, with a median of 35.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 49.8× | +13.6 |
| 2025 | Dec 31, 2025 | 36.1× | −334.3 |
| 2023 | Oct 31, 2023 | 370.4× | +187.1 |
| 2022 | Jul 29, 2022 | 183.3× | +46.6 |
| 2021 | Dec 31, 2021 | 136.7× | +103.3 |
| 2020 | Dec 31, 2020 | 33.4× | +29.7 |
| 2019 | Dec 31, 2019 | 3.7× | −6.6 |
| 2018 | Dec 31, 2018 | 10.3× | −58.5 |
| 2017 | Dec 29, 2017 | 68.8× | +67.8 |
| 2016 | Dec 30, 2016 | 1.0× | −0.7 |
| 2015 | Dec 31, 2015 | 1.7× | +1.6 |
| 2014 | Dec 31, 2014 | 0.1× | – |
See a number that looks wrong?